

A WORD FROM OUR CO-FOUNDER & DIRECTOR

The infrastructure for better health. Not just another supplement.

When we started Herbalwave, the question we asked was not “Which product can we sell?” It was:

“Which health need in Malaysia genuinely deserves a better answer?”

Kidney health, cognitive ageing, and immune resilience are not niche concerns. They represent meaningful health needs across Malaysian families — and opportunities for better, evidence-led solutions.

What follows is not a pitch for a single supplement. It is the beginning of an integrated nutraceutical and digital health ecosystem — combining proprietary products, evidence development, AI-powered medication interaction guidance, digital commerce, fulfilment and community-driven distribution.

Our approach has been deliberate. Before seeking capital, we established the foundations for product development and commercialization — including product registrations, formulation and manufacturing pathways, clinical and scientific expertise, and the infrastructure required to bring products to market.

We have built the foundation. The next stage is commercial execution. Your capital helps us move from readiness to traction.

We are not asking you to fund an idea. We are asking you to help activate a foundation already built — starting with Cordyna™ — and to be part of an evidence-led nutraceutical and digital health company built in Malaysia.

THE OPPORTUNITY

We have built the foundation. Now we are seeking the right partners to turn that foundation into commercial traction, scalable distribution and long-term value.

Thank you for taking the time to read further.

Dr. Lim Chin Chuan, MD

Co-Founder & Director
Herbalwave Sdn. Bhd.

The product is the entry point. The platform is the business.

Herbalwave is building an integrated nutraceutical and digital health ecosystem, combining evidence-led products with AI-powered medication interaction guidance, e-commerce, fulfilment and community-driven distribution — helping consumers make more informed decisions from discovery to purchase.

CLINICAL-LED NUTRACEUTICAL, DIGITAL HEALTH & INNOVATION ECOSYSTEM

Start with a real health need

CLINICAL-LED

We identify meaningful health needs and translate them into solutions.

Build differentiated solutions

NUTRACEUTICAL

Proprietary formulations for defined wellness and health segments.

Add an intelligence layer

DIGITAL HEALTH

AI-powered medication interaction guidance helps consumers make more informed decisions.

Own the route to market

ECOSYSTEM

E-commerce, fulfilment and CARE (Community Affiliate Reward Ecosystem) create an integrated customer acquisition and distribution engine.

VERTICAL INTEGRATION

Build once. Reuse across the portfolio.



The same infrastructure supports multiple proprietary products and new product formats.

WHY VERTICAL INTEGRATION MATTERS *We do not stop at product development.*

PORTFOLIO LEVERAGE

Cordyna™ → Memomax → Papavex
→ future Herbalwave IP

New products can reuse the same commercial infrastructure.

DISTRIBUTION LEVERAGE

Digital commerce → CARE → fulfilment

Centralized commerce and fulfilment infrastructure can support multiple products without duplicating the operating model.

ECOSYSTEM LEVERAGE

Customer trust → Authentication + Customer relationship

Each product strengthens the customer relationship, while the digital health layer creates additional opportunities for engagement and informed purchasing.

GENESIS → COMMERCIALISATION → SCALE

Genesis. First commercial activation: Cordyna™

Commercialisation. Portfolio expansion, e-commerce and CARE distribution

Scale. AI-powered digital health layer, technology and reusable infrastructure

INVESTMENT OPPORTUNITY

Herbalwave is seeking RM500,000 for 20% equity, at a RM2.5 million post-money valuation.

From incorporation to commercial activation.

Key milestones across clinical translation, formulation, research, regulatory readiness and commercialisation.

LEGEND	
●	Completed
●	In progress
○	Planned / 2026
2024	
Jul 2024	● Remedialam Sdn. Bhd. incorporated — IP holding company
Aug 2024	● Clinical needs assessment
Sep 2024	● Formulation development
Dec 2024	● OEM screening and selection
2025	
Mar 2025	● Formulation validation
Jun 2025	● Regulatory licence granted
Dec 2025	● NPRA registration
2026	
Jun 2026	● First production run
Jul 2026	● Research manuscript submitted — under peer review
Jul 2026	● Digital health & commerce platform activation
Sep 2026	● Herbalwave Sdn. Bhd. incorporated — exclusive commercialization rights
Sep 2026	● E-commerce marketing activation
Sep 2026	○ CARE affiliate and fulfillment activation
Sep 2026	○ AI medication interaction guidance — digital health layer

Remedialam Sdn. Bhd. holds the botanical IP. Herbalwave Sdn. Bhd. is its sole and exclusive commercialisation partner for Malaysia.

26 MONTHS, INCORPORATION TO ACTIVATION	10 MILESTONES COMPLETED	Q3 2026 COMMERCIAL ACTIVATION
--	----------------------------	----------------------------------

Three products. One commercial platform.

Herbalwave's initial portfolio comprises three proprietary nutraceutical formulations developed around defined health needs. Each product represents an additional health-focused IP asset that can plug into the same commercial infrastructure.



Cordyna™

KIDNEY WELLNESS & GUT-KIDNEY AXIS

A proprietary nutraceutical formulation targeting kidney wellness and the gut-kidney axis, developed around defined health needs.

MAL26066085TC



Memomax™

COGNITIVE WELLNESS & HEALTHY BRAIN AGEING

A proprietary nutraceutical formulation targeting cognitive wellness and healthy brain ageing, developed around defined health needs.

MAL26066093TC



Papavex™

IMMUNE & RECOVERY WELLNESS

A proprietary nutraceutical formulation targeting immune wellness and recovery, developed around defined health needs.

MAL26066062TC

REGULATORY FOUNDATION

FORMULATION & IP DEVELOPMENT

Developed by Remedialam Sdn. Bhd.

MAL REGISTERED GMP MANUFACTURED NPRA REGISTERED

COMMERCIALISATION & BRAND RIGHTS

Exclusively secured by Herbalwave Sdn. Bhd., with perpetual commercialisation and brand rights.


INVESTOR TAKEAWAY

The objective is not to commercialise one product, but to build an expanding portfolio of proprietary health IP — all leveraging the same digital and commercial infrastructure.


The market is fragmented. So is the value chain.

The opportunity is not simply another nutraceutical product. It lies in connecting clinical need, innovation and commercial access.

Clinical needs, product innovation, evidence development, digital commerce and distribution are often managed through separate organisations and systems. The result is a fragmented journey from health need to customer — with hand-offs that can create delays, costs, dependencies and limited visibility of the customer relationship.



WHERE VALUE CAN BE LOST



THE HERBALWAVE RESPONSE

INTEGRATE THE CHAIN — INSTEAD OF ADDING ANOTHER LINK


Herbalwave integrates clinical insight, nutraceutical IP, product development, AI-powered digital health, commerce and community distribution — creating a more integrated path from health need to customer.

Start with the health need. Not the herb.


A health-directed development model that translates identified health needs into proprietary nutraceutical solutions.

Many herbal products begin with an ingredient, a tradition or a broad wellness position. Herbalwave begins with an identified health need, then works backwards toward a suitable nutraceutical solution, formulation, evidence and a compliant commercial product.

CONVENTIONAL INGREDIENT-LED APPROACH



HERBALWAVE CLINICAL-LED APPROACH



POSITIONING + EVIDENCE

Cordyna™

KIDNEY HEALTH

Proprietary nutraceutical formulation developed around identified kidney-health needs, including the gut-kidney axis.

MAL26066085TC

Memomax™

BRAIN & COGNITIVE HEALTH

Proprietary nutraceutical formulation developed around identified cognitive-health and healthy brain-ageing needs.

MAL26066093TC

Papavex™

IMMUNE HEALTH

Proprietary nutraceutical formulation developed around identified immune-health and recovery needs.

MAL26066062TC

- Health-directed development, with product claims kept within the applicable NPRA framework.
- Scientific rationale, mechanism-of-action research and publication pathways are being developed as part of the evidence layer.
- Health-need direction does not by itself establish efficacy or therapeutic claims.

INVESTOR TAKEAWAY

Herbalwave starts with the health need — then works backwards through formulation, evidence and commercialisation to build the right solution.

Why the model compounds.

Build once. Reuse. Expand. Each product strengthens the platform for the next product.

Herbalwave is designed as a portfolio-led platform rather than a single-product business. The objective is to build reusable product, digital and commercial infrastructure — then leverage the same customer relationships, distribution, fulfilment and technology across a growing portfolio.

WHAT COMPOUNDS OVER TIME

IP ASSET BASE

Each new proprietary product expands the company's health-product asset base and portfolio optionality.

CUSTOMER ACCESS

Digital commerce and CARE provide reusable channels for customer acquisition and engagement across the portfolio.

DISTRIBUTION LEVERAGE

Existing commerce, CARE and fulfilment infrastructure can support additional products without rebuilding the route to market.

LEARNING LOOP

Customer interactions and commerce data inform future product and digital-health development.

HERBALWAVE COMMERCIAL FLYWHEEL

The ecosystem strengthens as the portfolio grows.

NUTRACEUTICAL IP

Proprietary formulations expand the portfolio.

DISTRIBUTION

E-commerce, CARE affiliates and fulfilment extend market reach.

CUSTOMER + DIGITAL HEALTH

Customer access, AI-powered medication interaction guidance and ongoing engagement deepen the customer relationship.

REVENUE + INSIGHTS

Commercial activity generates revenue and customer insights that inform further growth.

NEW PRODUCTS

Each launch returns to the same product, technology and commercial infrastructure.

Proprietary IP → customer acquisition → fulfilment → repeat purchase → portfolio expansion

The commercial engine is designed to make each additional product faster and more efficient to commercialize, because the underlying product, technology and distribution infrastructure is reusable.


INVESTOR TAKEAWAY

Products create the initial commercial entry. The reusable infrastructure creates the compounding value.


One platform. Multiple connected functions.

Connecting customer access, digital health, distribution, trust and operations through one integrated platform.


From customer discovery to fulfilment, one connected layer. The platform is designed to connect the commercial and digital-health journey — customer access, product information, AI-powered medication interaction guidance, member participation, distribution, rewards and operational visibility.



E-COMMERCE



CART & CHECKOUT



AUTHENTICATION

AUTHENTICATION MEETS COLLECTIBILITY

Each product carries a unique 10-digit authentication code designed to help deter counterfeiting and verify genuine products. Activation also creates a digital touchpoint between the product and Herbalwave's customer ecosystem, with a collectible card adding a physical layer to the experience.



Interfaces shown are development previews. Any displayed metrics are illustrative and not audited historical results.

AI-powered medication guidance. A new digital health layer.

Most supplement companies sell a product and end the relationship at checkout. Herbalwave is building an AI-powered health guidance layer that sits between the customer and the product — helping address a question many customers have before purchase: “Is this appropriate for me, given my medications and health circumstances?”

01 MEDICATION IDENTIFICATION

Upload or photograph your medications

The system helps identify the customer's medications and screens for potential interaction concerns relevant to the product.

02 HEALTH & CONTRAINDICATION SCREEN

Declare relevant health conditions

The customer provides relevant health information. The system screens for known contraindications and potential concerns, with appropriate cases directed for professional review.

03 REPORT TRANSLATION

Understand your health information

Lab reports can be translated into plain language to help customers understand relevant information and identify when professional advice may be appropriate.

04 GUIDED CONVERSATION

Talk it through

A conversational advisor helps clarify the customer's health concern and guides the next step — whether that is product information, further screening or referral to a clinician.

WHERE THE AI LAYER SITS

Screening before the sale, not marketing after it.

Customer arrives



AI wellness advisor —
medications, conditions, reports,
concern



Suitable product, or refer
to clinician



Ongoing relationship

SAFETY AS ACQUISITION

Helping a customer know when not to buy builds the trust that makes the broader portfolio more credible.

REUSABLE ACROSS THE PORTFOLIO

The same AI guidance infrastructure can be extended across Memomax™, Papavex™ and future products, with product-specific knowledge layered into the platform.

PROPRIETARY DATA LAYER

Customer questions, medication concerns and product interactions can generate structured insights that inform future product and digital-health development.

DEVELOPMENT STATUS

The conversational advisor begins development this week, with clinicians directly involved in training and shaping its health-language and guidance framework. Medication identification, contraindication screening and report translation will follow as subsequent capabilities within the Phase 2 intelligence layer.

The advisor is an information and product-guidance tool. It does not diagnose, treat or replace professional medical advice, and its outputs are subject to applicable NPRA requirements and appropriate clinical oversight.

INVESTOR TAKEAWAY

Competitors sell supplements. Herbalwave is building a digital health guidance layer that helps customers navigate medication, health and product-suitability questions — with clinical oversight, AI-assisted interaction screening and reusable infrastructure across the portfolio.

Market problems. Integrated responses.

A competitor can formulate a nutraceutical, launch an online store or build an affiliate network. Herbalwave integrates proprietary health IP, evidence development, AI-powered digital health, e-commerce, CARE distribution, fulfilment and customer relationships into one reusable commercial infrastructure.

LAYER	MARKET PROBLEM	HERBALWAVE RESPONSE
CLINICAL	01 Clinical-direction gap. Products may begin with an ingredient, tradition or broad wellness positioning.	Start with a defined health need and translate it into a targeted nutraceutical solution.
	02 Evidence gap. Evidence can be unclear or disconnected from the commercial product.	Expert-led research, scientific evaluation and evidence development around the product.
TRUST	03 Counterfeit risk. Customers may not be able to confirm product authenticity.	Unique product authentication codes linked to a digital verification and activation layer.
	04 Traceability gap. Product identity and batch information may be difficult to verify.	Digital product identity linked to product and batch information, supporting verification and traceability.
DIGITAL HEALTH	05 Medication & suitability gap. Customers may not know whether a supplement is appropriate alongside existing medication.	AI-powered health guidance designed to screen medication interactions and relevant contraindication concerns, with appropriate cases directed to professional review.
COMMERCIAL	06 Distribution & fulfilment gap. Reaching customers usually means depending on third-party retail and logistics.	Integrated e-commerce, CARE affiliate distribution and centralised fulfilment create a reusable route from customer acquisition to delivery.
	07 Commodity problem. Many nutraceutical products compete for attention through similar wellness positioning, price and marketing.	Differentiate through health-directed product development, proprietary formulations, evidence and trust infrastructure.
COMPLIANCE	08 Regulatory and quality uncertainty. Customers and partners need confidence in product registration, manufacturing standards and consistent product specifications.	NPRA-registered products, GMP-certified manufacturing and controlled product specifications provide a defined regulatory and quality foundation.
	09 Customer relationship gap. Traditional retail can separate the product from the customer and limit ongoing engagement.	Direct e-commerce, product activation and AI-powered health guidance create a more connected customer relationship.

INVESTOR TAKEAWAY

Herbalwave doesn't solve one market problem. It integrates responses across the value chain.

Health needs create defined target markets.

Herbalwave begins with identified health needs and translates them into defined health-need audiences. These figures illustrate the scale of the underlying needs and target populations.

01 IDENTIFY



02 DEFINE



03 VALIDATE



04 COMMERCIALISE

Cordyna™

KIDNEY HEALTH

15.5% CKD
PREVALENCE
2018

More than 5 million Malaysians are living with CKD.

TARGET AUDIENCE

Adults with identified kidney-health concerns and populations at elevated kidney-health risk.

Memomax™

BRAIN & COGNITIVE HEALTH

8.5% PROBABLE
DEMENTIA 60+,
NHMS 2018

A measurable cognitive-health burden among Malaysians aged 60+, with higher reported prevalence in rural populations.

TARGET AUDIENCE

Older adults and adults seeking support for cognitive wellness and healthy brain ageing.

Papavex™

IMMUNE HEALTH & RECOVERY

122,423 DENGUE
CASES
2024

An example of the infectious-disease burden creating demand for immune and recovery support.

TARGET AUDIENCE

People seeking immune and wellness support during periods of increased health demand/recovery.

EVIDENCE PIPELINE**Cordyna™**

Renal Protective, Oxidative-Inflammatory Regulation and Gut-Kidney Axis Support: A Malaysia-Focused Integrative Review of the Scientific Rationale Underlying the CORDYNA™ Formulation

Memomax™

A Multi-Target Nutraceutical Approach to Cognitive Health, Neuroprotection and Neuroplasticity Support: Scientific Rationale Underlying the MEMOMAX™ Formulation

MANUSCRIPTS UNDER PEER REVIEW**Papavex™**

PAPAVEX™: A Review of its Potential Roles in Immunoregulation, Cytokine Modulation and Febrile Wellness Support

Health-burden statistics illustrate market need; they do not establish efficacy or therapeutic claims for Cordyna™, Memomax™ or Papavex™. Product claims remain subject to applicable NPRA requirements.

INVESTOR TAKEAWAY

Defined health needs → defined audiences → focused product development → reusable commercial platform. Three initial products establish the portfolio; the same infrastructure can support future products addressing additional health needs.

From proprietary product to scalable revenue.

Herbalwave develops proprietary health products, then uses digital commerce, CARE and centralized fulfilment to acquire customers, fulfil orders and support repeat purchases across an expanding portfolio.

CARE — COMMUNITY-LED CUSTOMER ACQUISITION

Distribution without members carrying inventory.

NO INVENTORY LOADING Members do not need to carry product inventory.	CENTRALISED FULFILMENT Orders are handled through Herbalwave's centralised fulfilment infrastructure.	SIMPLE PARTICIPATION A straightforward community participation and reward model.	REWARD-LED ACQUISITION 5-20% basic CARE reward, with FIA (First Introduce Advantage) adding 5% where applicable.
--	---	--	--

FIA — FIRST INTRODUCE ADVANTAGE The first member to introduce a customer who completes a purchase earns an additional 5% on that customer's purchases of the same SKU for two years, regardless of channel. Designed to reward market education, not repeat transactions: the member who creates the first product connection retains the benefit as the customer continues purchasing that product.	<table><tr><td>REWARD</td><td>+5%</td></tr><tr><td>DURATION</td><td>2 years</td></tr><tr><td>SCOPE</td><td>Same SKU</td></tr><tr><td>CHANNEL</td><td>Any</td></tr></table>	REWARD	+5%	DURATION	2 years	SCOPE	Same SKU	CHANNEL	Any
REWARD	+5%								
DURATION	2 years								
SCOPE	Same SKU								
CHANNEL	Any								

PORTFOLIO LEVERAGE — ONE INFRASTRUCTURE, MANY PRODUCTS

PROPRIETARY IP Health-directed formulations	DIGITAL COMMERCE Customer acquisition	CARE NETWORK Community distribution	FULFILMENT Centralised operations	REPEAT PURCHASE Retention	NEW PRODUCTS Cross-pipeline expansion
---	---	---	---	-------------------------------------	---

PHASE 1 — GENESIS Build the proprietary product foundation across capsules, drinks and future delivery formats.	PHASE 2 — INTELLIGENCE + DISTRIBUTION Clinician-trained AI wellness advisor, medication interaction screening and automated distribution infrastructure.	PHASE 3 — MONITORING Connected monitoring to deepen long-term customer engagement and wellness support.
---	--	---

AI-FIRST OPERATING MODEL	Herbalwave is designed as an AI-centric company. The intention is to automate a large share of operational work — customer support, order processing, content, reporting and routine administration — so the business can scale volume and product lines while keeping headcount and fixed operating cost low.
---------------------------------	--

INVESTOR TAKEAWAY The same digital commerce, CARE and fulfilment infrastructure is reused as the portfolio expands, while existing customer relationships create leverage for cross-portfolio growth.

Unit economics → volume
→ contribution.

Illustrative planning scenarios showing how unit-level economics translate into annual contribution as volume scales.

At current planning assumptions, each unit generates positive contribution after product cost and CARE/FIA rewards. The model scales through repeatable unit sales, distribution expansion and reuse of the same commercial infrastructure.

ILLUSTRATIVE UNIT ECONOMICS

RM40	RM120–160	5–20% + 5%	RM50–104	41.7–65.0%
UNIT PRODUCT COST	SELLING PRICE	CARE + FIA	CONTRIBUTION	CONTRIBUTION MARGIN

Before overhead, tax and other operating costs. Shipping of RM8 is charged separately. Illustrative contribution assumes RM40 cost and up to 25% combined CARE/FIA rewards; the actual structure depends on the applicable reward tier.

ANNUAL VOLUME SCENARIOS

RM140 average selling price; RM72 contribution per unit.

ANNUAL UNITS	REVENUE @ RM140	PRODUCT COST	CARE + FIA @ 17.5%	CONTRIBUTION
10,000	RM 1,400,000	RM 400,000	RM 245,000	RM 755,000
20,000	RM 2,800,000	RM 800,000	RM 490,000	RM 1,510,000
50,000	RM 7,000,000	RM 2,000,000	RM 1,225,000	RM 3,775,000
100,000	RM 14,000,000	RM 4,000,000	RM 2,450,000	RM 7,550,000

Illustrative planning assumption: 17.5% combined CARE/FIA rewards.
RM7.0M illustrative annual product revenue and approximately RM3.8M illustrative contribution before overhead, tax and other operating costs.

01 PRODUCT ECONOMICS

Positive contribution is established at the unit level.

02 DISTRIBUTION EXPANSION

CARE supports customer acquisition without a conventional retail footprint.

03 INFRASTRUCTURE REUSE

New products use the same storefront, fulfilment and community infrastructure.

04 PORTFOLIO GROWTH

A broader portfolio creates more opportunities per customer.

IMPORTANT

Illustrative planning scenarios only. Actual results depend on realised selling price, product mix, volume, CARE/FIA structure, operating expenses, taxes and other commercial assumptions. Contribution is not net profit. The RM40 unit product cost is based on the current supply and manufacturing agreement with Remedialam.

Foundation built. Commercialisation next.

Genesis-stage company transitioning into first commercial activation. Herbalwave has progressed through product development, regulatory readiness, research, manufacturing, digital infrastructure and distribution development.

01 PRODUCT

- 3 proprietary formulations
- 2,000 Cordyna™ units ordered for initial commercial activation

02 REGULATORY + MANUFACTURING

- Cordyna™, Memomax™ and Papavex™ registered
- Commercial manufacturing pathway established

03 SCIENCE + EVIDENCE

- Formulation rationale
- Mechanism-of-action research
- Research manuscript submitted

04 DIGITAL INFRASTRUCTURE

- E-commerce, member system
- CARE rewards and product authentication
- Fulfilment and payout infrastructure
- AI wellness advisor entering development

05 DISTRIBUTION

- Digital acquisition channels in development
- Affiliate markets being engaged
- CARE network activation

GENESIS STAGE — TRANSPARENT POSITION

No commercial sales to date. The investment is intended to accelerate first commercial activation of the product, digital and distribution infrastructure already developed.

COMMERCIALISATION ROADMAP

NOW

Cordyna™

Initial 2,000-unit production order

MID-LATE SEP

Launch

First product enters commercial activation

END SEP

Platform

Digital platform targeted for initial activation

EARLY OCT

Ramp

Commercial operating ramp begins

~3 MONTHS

Evidence

Continued research and evidence development

PRODUCT ACTIVATION

Convert the initial Cordyna™ production order into commercial sales, customer activation and product feedback.

DIGITAL OPERATIONS

Bring e-commerce, member, authentication, rewards and fulfilment workflows into live operation.

CUSTOMER ACQUISITION

Activate digital, affiliate and CARE channels to establish repeatable customer acquisition.

EVIDENCE PIPELINE

Advance the evidence pipeline through continued scientific evaluation and manuscript development.

INVESTOR TAKEAWAY

Herbalwave is not starting from zero. The next milestone is commercial proof — converting an existing product, regulatory, scientific, digital and distribution foundation into repeatable revenue.

Capital to activate the commercial engine.

A defined external raise to accelerate first commercial activation and establish the foundation for scale.

RM500,000 TARGET EXTERNAL RAISE	RM2.5M POST-MONEY VALUATION	20% MAXIMUM AGGREGATE EXTERNAL EQUITY
---	---------------------------------------	---

ROUND STRUCTURE

RM2.0M pre-money + RM500K new capital = RM2.5M post-money

The RM500K raise represents 20% of the RM2.5M post-money valuation. The round is intended to accelerate commercial activation of the existing product, digital, distribution and fulfilment foundation.

WHAT THE CAPITAL ACTIVATES

The current plan does not prescribe a fixed percentage allocation across these layers.

01 PRODUCT COMMERCIALISATION Activate the first commercial product and establish the initial customer and sales base.	02 DIGITAL COMMERCE Bring e-commerce, membership, authentication, rewards and operating workflows into live use.	03 DISTRIBUTION Develop digital, affiliate and CARE community acquisition channels.	04 FULFILMENT + OPERATIONS Support reliable order processing and centralized fulfilment as sales begin to scale.
---	--	---	--

POTENTIAL FUTURE LIQUIDITY PATHWAYS

No fixed exit event is represented.

FUTURE FUNDING EVENT

A later institutional or strategic financing round could provide an opportunity for partial liquidity, depending on structure.

STRATEGIC TRANSACTION

Potential strategic investment, partnership or acquisition as Herbalwave's proprietary IP and commercial platform mature.

SECONDARY LIQUIDITY

Potential future share transfer or secondary transaction, subject to shareholder arrangements and applicable law.

LONG-TERM SHAREHOLDER VALUE

Value may also be realised through continued ownership as revenue, portfolio breadth and enterprise value develop.

Any liquidity event would depend on company performance, agreements and market conditions. Returns are not guaranteed.

INVESTOR POSITIONING

The opportunity is to enter before commercial proof is established. Capital accelerates the transition from Genesis → Commercialisation → Scale.

Three products.
Real health needs.

Herbalwave's three initial products are built around defined health needs and identifiable target populations in Malaysia. The opportunity is to translate these health needs into commercially addressable markets through focused product development and a reusable commercial platform.

REFERENCE BASE

The population relevant to the health need. It describes the scale of the underlying need, not a customer base.

SCENARIO LOGIC

Each scenario models what happens if a very small proportion of that reference base becomes a paying customer at a defined price and repeat frequency.

WHAT IT IS NOT

These are planning scenarios, not forecasts or a claim that the full reference base is addressable revenue.

TAM — TOTAL ADDRESSABLE MARKET

The full reference population relevant to the health need.

SAM — SERVICEABLE AVAILABLE MARKET

The share realistically targetable with the current product, positioning and business model.

SOM — SERVICEABLE OBTAINABLE MARKET

The share Herbalwave could realistically reach in the near term, given resources and execution capacity.

Cordyna™

> 5 million

Malaysians with CKD or kidney health burden (15.48% adult prevalence). A large and growing need driven by ageing, diabetes, hypertension and lifestyle factors.

LAYER	REFERENCE BASE	UNITS	REVENUE
TAM	5,000,000	20,000,000	RM2.80B
SAM 1%	50,000	200,000	RM28.0M
SOM 0.1%	5,000	20,000	RM2.80M

4 units per customer per year at RM140. Reaching 5,000 customers — 0.1% of the reference population — could generate about RM2.8 million in annual revenue.

Memomax™

~ 4.8 million

Malaysians aged 60 and above (15.3% of total population, 2024). Growing need for cognitive health support across an ageing population and working adults.

LAYER	REFERENCE BASE	UNITS	REVENUE
TAM	4,800,000	19,200,000	RM2.69B
SAM 1%	48,000	192,000	RM26.9M
SOM 0.1%	4,800	19,200	RM2.69M

4 units per customer per year at RM140. Reaching 4,800 customers — 0.1% of the reference population — could generate about RM2.69 million in annual revenue.

Papavex™

122,423

Reported dengue cases in Malaysia (2024). Significant need for immune support during acute illness and recovery periods.

LAYER	REFERENCE BASE	UNITS	REVENUE
TAM	122,423	122,423	RM17.1M
SAM 5%	6,121	6,121	RM856,940
SOM 2%	2,448	2,448	RM342,720

Acute use: 1 unit per customer at RM140. Reaching 2,448 customers — 2% of the reference base — could generate about RM342,720 in revenue. Papavex uses annual dengue incidence as an illustrative reference base for immune and recovery demand; it is not equivalent to an addressable customer population, and the same need extends to other viral and recovery contexts such as influenza and COVID-19.

Illustrative scenarios only. Actual market depends on product suitability, willingness to purchase, price, repeat frequency, acquisition cost and applicable regulatory claims. Health-burden statistics describe market need; they do not establish efficacy or therapeutic claims.

Risks acknowledged. Risks managed.

Commercial sales have not yet begun. The strategy is to launch in stages, validate the first product and acquisition economics, and scale only after measurable commercial evidence is established.

01 COMMERCIAL / DEMAND RISK

Risk. Product-market demand and repeat purchase behaviour have not yet been established.

Mitigation. Launch Cordyna™ first, measure initial sales and customer feedback, and validate repeat purchase behaviour before broader scale.

02 CUSTOMER ACQUISITION & DIGITAL HEALTH RISK

Risk. Digital acquisition channels and the AI guidance layer must prove useful, trusted and commercially sustainable.

Mitigation. Use multiple acquisition channels while developing the AI layer with clinician input and phased capability deployment.

03 PRODUCT CONCENTRATION RISK

Risk. The initial commercial phase begins with one lead product.

Mitigation. Use Cordyna™ as the first commercial wedge while maintaining a broader proprietary portfolio for subsequent expansion.

04 SUPPLY / FULFILMENT RISK

Risk. Early growth can create operational pressure around production, fulfilment and customer service.

Mitigation. Controlled manufacturing and centralized fulfilment, with the initial Cordyna™ order providing a defined commercial starting point.

05 SCIENTIFIC / EVIDENCE RISK

Risk. Research and manuscripts remain subject to scientific review and publication outcomes.


Mitigation. Continue evidence development and peer review without representing unpublished work as established clinical evidence.

06 REGULATORY / CLAIMS RISK

Risk. Health-product claims and communications must remain within applicable requirements.

Mitigation. Maintain disciplined product positioning and regulatory compliance; separate market-need data from efficacy claims.

THE DE-RISKING SEQUENCE



INVESTOR TAKEAWAY

The objective is not to eliminate early-stage risk. It is to manage it through staged validation, with capital deployed toward commercial activation and scaling decisions informed by real market evidence.

Clinical need in. Product direction out.

Dr. Lim Chin Chuan is Co-Founder, Executive Director and Medical Director. A physician with over 15 years of clinical experience, he identifies unmet health needs in clinical practice and translates them into practical herbal and nutraceutical product concepts.



Dr. Lim Chin Chuan, MD

Co-Founder, Executive Director & Medical Director

Founder & Director, Remedialam Sdn. Bhd.

Doctor of Medicine, MD — I. M. Sechenov
(Russia)

Diploma in Herbalogy — India

HIS CONTRIBUTION

Dr. Lim brings the clinical and medical perspective to Herbalwave, identifying healthcare needs and translating clinical observations into practical herbal and nutraceutical product concepts. He directs these concepts toward research and scientific evaluation, working with the research function to establish the supporting evidence while contributing to executive direction and product strategy.

Medical leadership · Translational medicine · Herbal product development

ROLE AT HERBALWAVE



CLINICAL MEDICINE

15+ years of clinical practice, providing direct insight into patient needs, disease presentation and practical healthcare applications.

RESEARCH & PUBLICATION

First author of a peer-reviewed review article on nutraceutical synergies, published in the Bangladesh Journal of Medical Science.

PROPRIETARY FORMULATIONS

Cordyna™ (kidney health), Memomax™ (brain & cognitive health) and Papavex™ (immune health & recovery) — product concepts developed from identified clinical needs and translated into formulations through Remedialam Sdn. Bhd.

WHY IT MATTERS

Product direction begins with a clinician who sees the need firsthand — keeping the portfolio anchored to real health problems rather than ingredient trends.

From scientific evidence to economic value.

Associate Professor Dr. Lim Chin Choon is Co-Founder, Chief Investor and Compliance Officer. A pharmacology and health-economics researcher, he brings pharmacoeconomic evaluation to investment decisions, governance and compliance.



Assoc. Prof. Dr. Lim Chin Choon, MBBS, PhD

Co-Founder, Chief Investor & Compliance Officer

MBBS— Universiti Malaya
Master in Pharmacology— International Islamic University Malaysia
PhD in Pharmacoeconomics
(Pharmacoeconomics & Outcome Research)
— Universiti Sains Malaysia

HIS CONTRIBUTION

Connecting scientific evidence, economic evaluation and strategic decisions. His expertise in pharmacology, health outcomes and pharmacoeconomics supports product evaluation, investment decisions and compliance, helping Herbalwave align evidence development with long-term commercial value.

Pharmacoeconomics · Health outcomes research · Governance and compliance

FROM SCIENCE TO VALUE



CORE EXPERTISE

Pharmacoeconomics and health economics; health outcomes research; evidence-based decision making; compliance and risk management; investment and strategic analysis.

ROLE AT HERBALWAVE

Identify and evaluate investment opportunities, apply health-economics principles to resource allocation, and provide oversight on regulatory compliance, corporate governance and risk management.

SELECTED PUBLICATIONS

Enhancing skin health: the role of nutraceutical synergies in counteracting the signs of aging. *Bangladesh Journal of Medical Science* (2025).
Evaluation of lifetime cost-effectiveness of childhood obesity programme in Malaysia (2022).
Systematic review of economic evaluation models for childhood obesity (2022).
Pilot evaluation of two childhood obesity prevention programmes in Malaysia (2015).

WHY IT MATTERS

Investment, evidence and compliance are assessed inside the company through a health-economics lens, helping keep product claims disciplined and capital allocation tied to measurable value.

Concepts become products only after validation.

Providing scientific leadership to evaluate, validate and advance the product pipeline through evidence-based research. Dr. Hasbullani designs research approaches, guides scientific testing and helps prepare research findings for publication and evidence development.



**Dr. Hasbullani bin Zakaria,
PhD**

Scientific Research Lead / Research Partner

PhD in Pharmacology and Toxicology —
Universiti Teknologi MARA (UiTM)

HIS CONTRIBUTION

Providing scientific leadership to evaluate, validate and develop the product pipeline through evidence-based research. Dr. Hasbullani designs research approaches, guides scientific testing and helps prepare research findings for publication and evidence development.

Research leadership · Natural products · Pharmacology · Evidence translation

ROLE AT HERBALWAVE



MEDICINAL PLANT RESEARCH

Research involving *Apium graveolens* and *Myrmecodia* species, exploring applications in chronic disease and health science.

MYRMECODIA PLATYTYREA

Phytochemical composition, antioxidant and antidiabetic properties studied using in-vitro and in-vivo models.

PHARMACOGENOMICS

Research on HLA-B*15:02 and carbamazepine-induced severe drug reactions, and pharmacogenetic factors in personalised 5-fluorouracil therapy.

Selected publications: *South African Journal of Botany* (2018) · *Journal of Chromatography A* (2017) · *Indonesian Journal of Pharmacy* (2021) · *International Journal of Pharmacy and Pharmaceutical Sciences* (2016) · *Therapeutic Drug Monitoring* (2013) · *Clinical Laboratory* (2012).

WHY IT MATTERS

Each product concept is subject to scientific evaluation before commercial development, with the same research function supporting the evidence and publication pipeline.

CORDYNA™
From Scientific Research to
Commercialization

EVIDENCE-INFORMED KIDNEY WELLNESS
& GUT-KIDNEY AXIS SUPPORT

A Proprietary Multi-Pathway
Formulation



MAL26066085TC

NPRA REGISTERED

Registered with the National
Pharmaceutical Regulatory Agency
(NPRA), Malaysia.



Proprietary
Formulation

Multi-component
kidney wellness
formulation developed
by Remedialam Sdn.
Bhd.



MAL
Registered

MAL26066085TC
Registered with the
National
Pharmaceutical
Regulatory Agency
(NPRA), Malaysia.



Scientific
Manuscript
Submitted

Scientific manuscript
submitted to an
international peer-
reviewed journal.



Commercialization
Ready

Manufacturing
pathway established
with branding and
commercialization
assets completed.



Exclusive
Licensing
Rights

Exclusive
Commercialization
Rights Granted to
Herbalwave Sdn. Bhd.

PRODUCT OVERVIEW

CORDYNA targets the growing kidney wellness market through a proprietary botanical formulation supported by scientific validation and regulatory readiness.

- Kidney Function Support
- Nephroprotective Support
- Oxidative & Inflammatory Regulation
- Physiological Fluid Balance
- Gut-Kidney Axis Wellness

Scientifically Studied Ingredients:



Cordyceps
sinensis



Astragalus
membranaceus



Curcuma
xanthorrhiza



Orthosiphon
stamineus



Acacia
senegal



Poria
cocos

These ingredients were selected for their complementary roles in renal wellness, metabolic regulation and healthy aging.

RESEARCH OVERVIEW

- PRISMA-Guided Methodology
- 443 Total Records Identified
- 335 Records Screened
- 89 Full-Text Articles Assessed
- 57 Scientific Studies Included
- 5 International Databases Reviewed
- Comprehensive Integrative Review Completed and Submitted for International Peer Review



57

SCIENTIFIC
REFERENCES



443

SCIENTIFIC
STUDIES



89

FULL-TEXT
ARTICLES
REVIEWED



5

DATABASES
REVIEWED

PRISMA METHODOLOGY

STRATEGIC ASSETS

- Proprietary Formulation
- NPRA Registered Product
- Evidence-Informed Development
- Scientific Manuscript Submitted
- Kidney Wellness Positioning
- Exclusive Commercialization Rights

SCIENTIFIC PUBLICATION PATHWAY

Title:

Renal Protection, Oxidative-inflammatory Regulation and Gut-Kidney Axis Support: A Malaysia-Focused Integrative Review of the Scientific Rationale Underlying the CORDYNA™ Formulation.

Background: CKD is a growing health burden, creating a need for complementary multi-target strategies to support kidney health.

Objective: To evaluate the scientific evidence supporting the renal-supportive potential of CORDYNA™ and its six botanical ingredients.

Methods: A PRISMA-guided integrative literature review analyzed 57 eligible studies from five scientific databases.

Results: The ingredients demonstrated potential antioxidant, anti-inflammatory, nephroprotective, urinary, metabolic, fluid-regulating and gut-kidney axis benefits.

Conclusion: CORDYNA™ has a promising multi-pathway scientific rationale for adjunctive kidney-health support, but clinical studies of the complete formulation are still needed.

Scientific manuscript completed and submitted to an international peer-reviewed journal.

MARKET OPPORTUNITY

People living with CKD globally	~ 850 MILLION
CKD prevalence among Malaysian adults (2018)	15.48%
Patients receiving dialysis treatment in Malaysia	57,000+
Malaysians with diabetes (2019)	3.9 MILLION (18.3%)
Malaysians with hypertension (2023)	5.5 MILLION (29.2%)
Projected ESRD patients requiring dialysis by 2040	~106,000

Sources: NHMS 2023; National Renal Registry Malaysia 2022; IDF Diabetes Atlas 2024; Institute for Health Metrics and Evaluation (IHME) 2023.

KEY SCIENTIFIC FOCUS AREAS



KIDNEY FUNCTION SUPPORT:
Supports healthy kidney
function and physiological
filtration.



FLUID BALANCE SUPPORT:
Supports healthy fluid balance
and electrolyte homeostasis.



GUT-KIDNEY AXIS SUPPORT:
Supports gut health and
pathways relevant to the gut-
kidney axis.



NEPHROPROTECTIVE SUPPORT:
Supports antioxidant defence and
oxidative-stress regulation.



OXIDATIVE STRESS REGULATION:
Supports antioxidant defence and
healthy oxidative balance.



INVESTMENT HIGHLIGHTS

CORDYNA™ demonstrates Herbalwave's ability to develop and commercialize evidence-based kidney wellness products supported by scientific validation, NPRA registration and a clear pathway to commercialization.

MEMOMAX™

From Scientific Research to Commercialization

EVIDENCE-INFORMED COGNITIVE WELLNESS & HEALTHY BRAIN AGING

A Proprietary Multi-Pathway Formulation



MAL26066093TC

NPRA REGISTERED

Registered with the National Pharmaceutical Regulatory Agency (NPRA), Malaysia.



Proprietary Formulation

Multi-component brain & cognitive wellness formulation developed by Remedialam Sdn. Bhd.



MAL Registered

MAL26066093TC Registered with the National Pharmaceutical Regulatory Agency (NPRA), Malaysia.



Scientific Manuscript Submitted

Scientific manuscript submitted to an international peer-reviewed journal.



Commercialization Ready

Manufacturing pathway established with branding and commercialization assets completed.



Exclusive Licensing Rights

Exclusive Commercialization Rights Granted to Herbalwave Sdn. Bhd.

PRODUCT OVERVIEW

MEMOMAX™ targets the rapidly growing cognitive wellness and healthy ageing market through an evidence-informed multi-component formulation designed to support memory, cognitive performance, neuroprotection and long-term brain health.

- Memory & Cognition Support
- Neuroprotection Support
- Neuroplasticity Support
- Cerebrovascular Health
- Stress Resilience
- Healthy Brain Aging

Scientifically Studied Ingredients:



Hericium erinaceus



Bacopa monnieri



Pinus pinaster



Withania somnifera



Camellia sinensis



Centella asiatica



Ginkgo biloba

These ingredients were selected for their complementary roles in memory support, cognitive performance, neuroprotection and long-term brain health.

RESEARCH OVERVIEW

- PRISMA-Guided Methodology
- 410 Total Records Identified
- 293 Records Screened
- 97 Full-Text Articles Assessed
- 53 Scientific Studies Included
- 4 International Databases Reviewed
- Comprehensive Integrative Review Completed and Submitted for International Peer Review



53

SCIENTIFIC REFERENCES



410

SCIENTIFIC STUDIES



97

FULL-TEXT ARTICLES REVIEWED



4

DATABASES REVIEWED

PRISMA METHODOLOGY

STRATEGIC ASSETS

- Proprietary Formulation
- NPRA Registered Product
- Evidence-Informed Development
- Scientific Manuscript Submitted
- Brain & Cognitive Wellness Positioning
- Exclusive Commercialization Rights

SCIENTIFIC PUBLICATION PATHWAY

Title:

A Multi-Target Nutraceutical Approach to Cognitive Health, Neuroprotection and Neuroplasticity Support: Scientific Rationale Underlying the MEMOMAX™ Formulation

Background: Cognitive decline, chronic stress and age-related neurological changes are growing concerns, highlighting the need for complementary strategies supporting cognitive health and healthy brain aging.

Methods: A PRISMA-guided integrative literature review identified 410 records, with 53 scientific studies included in the final evidence synthesis from four scientific databases and additional sources.

Results: The ingredients demonstrated biologically plausible cognitive-supportive, neuroprotective, antioxidant, neuroplasticity, cerebrovascular and stress-modulating activities across multiple interconnected pathways.

Conclusion: MEMOMAX™ has a promising multi-target scientific rationale for cognitive wellness, neuroprotection and healthy brain aging, although clinical evaluation of the complete formulation remains necessary.

Scientific manuscript completed and submitted to an international peer-reviewed journal.

MARKET OPPORTUNITY

People living with dementia globally (2023)	55 MILLION
Projected global dementia population by 2050	139 MILLION
People with mild cognitive impairment globally	200 MILLION
Malaysian population aged 60 years and above (2023)	3.7 MILLION (11%)
Projected Malaysian population aged 60+ by 2040	5.7 MILLION (15%)

Sources: Alzheimer's Disease International (World Alzheimer Report 2023); WHO (2023); Ministry of Health Malaysia (NHMS 2023); UN DESA World Population Aging (2023).

KEY SCIENTIFIC FOCUS AREAS



MEMORY & COGNITION SUPPORT: Supports memory, learning and overall cognitive performance.



NEUROPLASTICITY SUPPORT: Supports synaptic plasticity and BDNF signalling pathways.



HEALTHY BRAIN AGING: Supports long-term brain health and longevity.



NEUROPROTECTIVE SUPPORT: Supports neuronal protection against oxidative stress and inflammation.



CEREBROVASCULAR HEALTH: Supports healthy blood flow, oxygen and nutrient supply to the brain.



STRESS RESILIENCE: Supports healthy stress response and mental well-being.

INVESTMENT HIGHLIGHTS



MEMOMAX™ demonstrates Herbalwave's ability to develop and commercialize evidence-informed cognitive wellness products supported by scientific validation, NPRA registration and a clear pathway to commercialization

PAPAVEX™

From Scientific Research to Commercialization

EVIDENCE-INFORMED IMMUNE AND RECOVERY WELLNESS

A Proprietary Multi-Pathway Formulation



Proprietary Formulation

Multi-component immune and recovery wellness formulation developed by Remedialam Sdn. Bhd.



MAL Registered

MAL26036062TC Registered with the National Pharmaceutical Regulatory Agency (NPRA), Malaysia.



Scientific Manuscript Submitted

Scientific manuscript submitted to an international peer-reviewed journal.



Commercialization Ready

Manufacturing pathway established with branding and commercialization assets completed.



Exclusive Licensing Rights

Exclusive Commercialization Rights Granted to Herbalwave Sdn. Bhd.

PRODUCT OVERVIEW

PAPAVEX™ addresses the growing immune wellness and recovery-support market through a proprietary botanical formulation supported by scientific evidence and regulatory readiness.

- Immune Regulation
- Cytokine Balance
- Oxidative Stress Modulation
- Physiological Recovery Support
- Respiratory Wellness


Scientifically Studied Ingredients:



Carica papaya



Andrographis paniculata



Tinospora cordifolia



Euphorbia hirta



Acerola fruit extract

These ingredients were selected for their complementary roles in immune homeostasis, inflammatory balance and recovery support.



MAL26036062TC

NPRA REGISTERED

Registered with the National Pharmaceutical Regulatory Agency (NPRA), Malaysia.

HEALTH BURDEN & MARKET OPPORTUNITY

Estimated dengue infections globally each year	100-400 MILLION
Dengue cases reported in Malaysia (2024)	122,423 CASES
Seasonal influenza cases globally each year	~1 BILLION
Severe influenza cases globally each year	3-5 MILLION
People with COVID-19 estimated to develop post-COVID-19 condition	~6%

Sources: WHO (Dengue, 2025); Ministry of Health Malaysia (Annual Report 2024); WHO (Influenza, 2025); WHO (Post COVID-19 Condition, 2025).

RESEARCH OVERVIEW

- PRISMA-Guided Methodology
- 509 Total Records Identified
- 353 Records Screened
- 125 Full-Text Articles Assessed
- 56 Scientific Studies Included
- 5 International Databases Reviewed
- Comprehensive Integrative Review Completed and Submitted for International Peer Review



56

SCIENTIFIC REFERENCES



509

SCIENTIFIC STUDIES



125

FULL-TEXT ARTICLES REVIEWED



5

DATABASES REVIEWED

PRISMA METHODOLOGY

STRATEGIC ASSETS

- Proprietary Formulation
- NPRA Registered Product
- Evidence-Informed Development
- Scientific Manuscript Submitted
- Immune & Recovery Wellness Positioning
- Exclusive Commercialization Rights

SCIENTIFIC PUBLICATION PATHWAY

Title:

PAPAVEX™: A Review of Its Potential Roles in Immunoregulation, Cytokine Modulation, and Febrile Wellness Support

Background: Viral febrile illnesses are associated with immune dysregulation, oxidative stress, cytokine activation, fatigue and delayed physiological recovery.

Methods: A PRISMA-guided integrative literature review identified 509 records, with 56 studies included in the final narrative synthesis.

Results: The ingredients demonstrated biologically plausible antioxidant, immunomodulatory, cytokine-regulatory, inflammatory-modulating and recovery-supportive activities.

Conclusion: PAPAVEX™ represents a multi-target supportive formulation for immune wellness and physiological recovery, although further formulation-specific clinical evaluation remains necessary.

Scientific manuscript completed and submitted to an international peer-reviewed journal.

INVESTMENT HIGHLIGHTS



PAPAVEX™ demonstrates Herbalwave's capability to develop and commercialize evidence-informed wellness products, supported by scientific evidence, NPRA registration and a clear commercialization pathway.

KEY SCIENTIFIC FOCUS AREAS



IMMUNE REGULATION SUPPORT: Supports balanced immune response and homeostasis



CYTOKINE MODULATION: Helps modulate cytokine activation and inflammatory mediators.



RESPIRATORY WELLNESS: Supports respiratory health and wellness maintenance.



ANTIOXIDANT DEFENCE: Supports antioxidant defence against oxidative stress.



RECOVERY SUPPORT: Supports physiological recovery, vitality and overall wellness.

QUEST 3+

Product Information / Maklumat Produk

Product Name :

HERBALWAVE CORDYNA CAPSULE

Holder :

REMEDIALAM SDN. BHD.

Registration No :

MAL26066085TC

Holder Address :

**NO. 71A, TAMAN VOKASIONAL,
07000
LANGKAWI
MALAYSIA**

Phone No :

0109628916

Manufacturer :

Manufacturer Address :

Ingredients Information / Maklumat Bahan Aktif

No Active Ingredient

- 1 Cordyceps sinensis
- 2 Astragalus membranaceus
- 3 Orthosiphon stamineus
- 4 Curcuma xanthorrhiza
- 5 Acacia senegal
- 6 Poria cocos

Packaging Information / Maklumat Bungkusan

No Quantity

- 1 30 Capsules
- 2 60 Capsules
- 3 90 Capsules

QUEST 3+

Product Information / Maklumat Produk

Product Name :

HERBALWAVE MEMOMAX CAPSULE

Holder :

REMEDIALAM SDN. BHD.

Registration No :

MAL26066093TC

Holder Address :

**NO. 71A, TAMAN VOKASIONAL,
07000
LANGKAWI
MALAYSIA**

Phone No :

0109628916

Manufacturer :

Manufacturer Address :

Ingredients Information / Maklumat Bahan Aktif

No Active Ingredient

- 1 Hericium erinaceus
- 2 Bacopa monnieri
- 3 Pinus pinaster
- 4 Withania somnifera
- 5 Camellia sinensis
- 6 Centella asiatica
- 7 Ginkgo biloba

Packaging Information / Maklumat Bungkusan

No Quantity

- 1 30 Capsules
- 2 60 Capsules
- 3 90 Capsules

QUEST 3+

Product Information / Maklumat Produk

Product Name :

HERBALWAVE PPAVEX CAPSULE

Holder :

REMEDIALAM SDN. BHD.

Phone No :

0109628916

Manufacturer :

Registration No :

MAL26036062TC

Holder Address :

**NO. 71A, TAMAN VOKASIONAL,
07000
LANGKAWI
MALAYSIA**

Manufacturer Address :

Ingredients Information / Maklumat Bahan Aktif

No Active Ingredient

- 1 Carica papaya
- 2 Euphorbia hirta
- 3 Malpighia emarginata
- 4 Tinospora cordifolia
- 5 Andrographis paniculata

Packaging Information / Maklumat Bungkusan

No Quantity

- 1 30 Capsules
- 2 60 Capsules
- 3 90 Capsules